CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer.
Selzer
M G
MG
Department of Urology (M-800), University of Miami, Florida 33101, USA.
Zhu
B
B
Block
N L
NL
Lokeshwar
B L
BL
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D008297:Male; D010264:Paraplegia / Q000209:etiology / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D011480:Protease Inhibitors / Q000627:therapeutic use*; D051381:Rats; D013754:Tetracyclines / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D000970:Antineoplastic Agents; D011480:Protease Inhibitors; D013754:Tetracyclines; C117155:tetracycline CMT-3